Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“Tumor Lysis Syndrome 2025.
Incidence 5-70%, highest in acute leukemias and lymphomas. Now increasingly associated with targeted therapies and ICIs, even in solid tumors. ICIs >150 cases, 44% mortality.
Stratify risk, prophylaxis and act fast.”
Title: Tumor Lysis Syndrome
Authors: R. Gregory Bociek, and Matthew Lunning.
Read The Full Article at NEJM.
More posts featuring O. Tahuahua.